ArticleBlood2017
Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion.
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 59 citations in OpenAlex.
- Investigational New Drug-enabling studies in a human vessel-chip: Are we there yet?Bioengineering & translational medicine · 2026Review
- Ubiquitination and degradation of CD47 enhances macrophage phagocytosis of hemolytic erythrocytes.iScience · 2026Article
- Microfluidic Chip Platforms for Red Blood Cell Storage Lesion Quality Control and Precision Transfusion.Research (Washington, D.C.) · 2026Review
- Emergency care for children with sickle cell disease: a focus on pain and fever.Expert review of hematology · 2025Review
- Guidelines for the management of emergencies and critical illness in pediatric and adult patients with sickle cell disease.Annals of intensive care · 2025Review
- Emergency department intravenous fluid resuscitation and renal outcomes among adults with sickle cell disease.American journal of hematology · 2025Article
- Charting the Waters of Sickle Cell Disease With Target Trial Emulation.JAMA internal medicine · 2024Article
- Association of baseline serum sodium with long-term outcomes in newly diagnosed coronary heart disease patients without heart failure: a prospective cohort study.Scientific reports · 2024Article
- Intravenous fluid therapy and hospital outcomes for vaso-occlusive episodes in children, adolescents, and young adults with sickle cell disease.Pediatric blood & cancer · 2024Article
- Review
- Hypothermal opto-thermophoretic tweezers.Nature communications · 2023Article
- iCLOTS: open-source, artificial intelligence-enabled software for analyses of blood cells in microfluidic and microscopy-based assays.Nature communications · 2023Article
- Hypothermal opto-thermophoretic tweezers.Research square · 2023Article
- Hyperviscosity syndromes; hemorheology for physicians and the use of microfluidic devices.Current opinion in hematology · 2022Review
- Intravenous Fluid Administration and the Risk of Adverse Outcomes in Sickle Cell Disease Patients Hospitalized for Vaso-Occlusive Crisis.Journal of hematology · 2022Review
- Microfluidics in vascular biology research: a critical review for engineers, biologists, and clinicians.Lab on a chip · 2022Review
- Microfluidic methods to advance mechanistic understanding and translational research in sickle cell disease.Translational research : the journal of laboratory and clinical medicine · 2022Review
- Prevalence and outcomes of dehydration in adults with sickle cell trait: the Atherosclerosis Risk in Communities (ARIC) study.British journal of haematology · 2022Article
- Ionophore-mediated swelling of erythrocytes as a therapeutic mechanism in sickle cell disease.Haematologica · 2022Article
- Time to rethink haemoglobin threshold guidelines in sickle cell disease.British journal of haematology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Abnormal sickle red blood cell (sRBC) biomechanics, including pathological deformability and adhesion, correlate with clinical severity in sickle cell disease (SCD). Clinical intravenous fluids (IVFs) of various tonicities are often used during treatment of vaso-occlusive pain episodes (VOE), the major cause of morbidity in SCD. However, evidence-based guidelines are lacking, and there is no consensus regarding which IVFs to use during VOE. Further, it is unknown how altering extracellular fluid tonicity with IVFs affects sRBC biomechanics in the microcirculation, where vaso-occlusion takes place. Here, we report how altering extracellular fluid tonicity with admixtures of clinical IVFs affects sRBC biomechanical properties by leveraging novel in vitro microfluidic models of the microcirculation, including 1 capable of deoxygenating the sRBC environment to monitor changes in microchannel occlusion risk and an "endothelialized" microvascular model that measures alterations in sRBC/endothelium adhesion under postcapillary venular conditions. Admixtures with higher tonicities (sodium = 141 mEq/L) affected sRBC biomechanics by decreasing sRBC deformability, increasing sRBC occlusion under normoxic and hypoxic conditions, and increasing sRBC adhesion in our microfluidic human microvasculature models. Admixtures with excessive hypotonicity (sodium = 103 mEq/L), in contrast, decreased sRBC adhesion, but overswelling prolonged sRBC transit times in capillary-sized microchannels. Admixtures with intermediate tonicities (sodium = 111-122 mEq/L) resulted in optimal changes in sRBC biomechanics, thereby reducing the risk for vaso-occlusion in our models. These results have significant translational implications for patients with SCD and warrant a large-scale prospective clinical study addressing optimal IVF management during VOE in SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.